BrainStorm Cell Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Corporate Update

/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...

Related Keywords

California ,United States ,Massachusetts ,John Mullaly ,Jeffrey Cohen ,Seanm Healey ,Chaim Lebovits ,Lisa Guiterman ,Stacy Lindborg ,Brainstorm Cell Therapeutics Inc ,California Institute For Regenerative Medicine ,Lifesci Advisors ,Mellen Center ,Cleveland Clinic Lerner College Of Medicine ,Drug Administration ,Advisory Committee ,Nasdaq ,Research Symposium ,National Ms Society ,European Medicines Agency ,Research In Multiple Sclerosis ,European Committee For Treatment ,Biologics License ,Brainstorm Cell Therapeutics ,Biologics License Application ,Chief Executive Officer ,Earnings Call ,New Biologics License Application ,Rating Scale ,Executive Vice President ,Chief Development Officer ,Merit Cudkowicz ,Massachusetts General Hospital ,Julieanne Dorn Professor ,Harvard Medical School ,Massachusetts General ,Multiple Sclerosis Journal The ,Comprehensive Longitudinal Investigation ,Multiple Sclerosis ,European Committee ,Hazel Prior Hostetler Endowed Chair ,Cleveland Clinic Lerner College ,Experimental Therapeutics ,Third Quarter Ended September ,Storm Cell Therapeutics ,Orphan Drug ,California Institute ,Regenerative Medicine ,Harbor Statement ,Sci Advisors ,Term Assets ,Term Liabilities ,Banking Amp Financial Services ,Computer Software ,Medical Pharmaceuticals ,Health Care Amp Hospitals ,Biotechnology ,Earnings ,